Director, Clinical Pharmacology

Remix Therapeutics is a clinical-stage biotechnology company developing novel small molecule therapies designed to reprogram RNA processing and address disease drivers at their origin. Remix's REMaster™ technology platform leverages data science, biomolecular sciences and chemistry approaches to identify orally administered compounds that modulate gene expression. Remix's therapeutic approach led to the discovery of REM-422, an investigational small molecule designed to modulate RNA processing in oncology, currently being evaluated in two clinical programs, 1) the ARIA clinical study, a Phase 1/2 clinical study in adenoid cystic carcinoma (ACC), and 2) a Phase 1 clinical study in acute myeloid leukemia (AML) and high-risk myelodysplastic syndrome (HR-MDS).

Position Summary:

The Director of Clinical Pharmacology will play a critical role in the design, execution, analysis, and interpretation of clinical pharmacology strategies across Remix Therapeutics' development programs. The initial focus of the role will be to lead the integrated clinical pharmacology strategy for REM-422, with primary responsibility for supporting late-stage development and potential regulatory submissions. The role will also provide clinical pharmacology leadership for emerging pipeline programs to support IND-enabling and early clinical development strategies.

The successful candidate will work in